BMO Capital Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $1082
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan David Seigerman maintains an Outperform rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raises the price target from $1055 to $1082.
February 05, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital maintains an Outperform rating on Regeneron Pharmaceuticals and raises the price target from $1055 to $1082.
The increase in price target by BMO Capital indicates a strong confidence in Regeneron Pharmaceuticals' future performance. This positive analyst rating and raised price target are likely to instill investor confidence, potentially leading to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100